Incyte beats on earnings, revenue–but drops on lack of improved guidance

Incyte beats on earnings, revenue–but drops on lack of improved guidance

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Analyst upgrade is catalyst for 6.17% jump in Acadia Pharmaceuticals today

Analyst upgrade is catalyst for 6.17% jump in Acadia Pharmaceuticals today

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Incyte beats on earnings, revenue–but drops on lack of improved guidance

Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

Trump administration picks five coronavirus vaccine efforts to receive big government funding

Trump administration picks five coronavirus vaccine efforts to receive big government funding

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200

AbbVie continues its run–picks up momentum from Allergan results

AbbVie continues its run–picks up momentum from Allergan results

This page is for Subscribers.

We’ll share all of our Posts and our Live Public Portfolios with you!

Sign Up for a subscription and you can view everything on the Juggling With Knives website. (If you’ve purchased the book, you’ve earned a free subscription. Use the Coupon Code in the book to start your one-year FREE subscription).

Plus, you’ll get Jim’s Volatility Email Update each evening at 8:00pm.

SignUpButton200